Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee to Review Second SGLT-2 Inhibitor Dapagliflozin on Jan 24
January 15, 2014
- MHLW Begins Probe into Suspected Data-Tampering of J-ADNI Project
January 15, 2014
- MHLW to Decide Measures by March 2014 to Improve Price Settlement Rates: Ministry Official
January 14, 2014
- Diovan Scandal Could Undermine Confidence in Clinical Studies: Minister Tamura
January 14, 2014
- MHLW Proposes that Medical Institutions Clarify in Invoices that Consumption Tax Is Included in Drug Prices
January 14, 2014
- Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
- MHLW Seeks Criminal Charges against Novartis over Suspected PAL Violations, Diovan Ads Allegedly Misleading
January 10, 2014
- MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
- Guidance on Companion Diagnostics Calls for Inclusion of Biomarker-Negative Subjects in Clinical Studies
January 8, 2014
- MHLW Adds Precaution for Driving in Package Inserts of Donepezil and Other Drugs
January 8, 2014
- MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
- MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
- HSB Invites Additional Applicants for New Flu Vaccine Development and Production Project
January 7, 2014
- Discarded Plan to Institutionalize Key Premium Still Faces Backlash; Rough Sailing Expected before Next Reform
December 27, 2013
- Shiga University of Medical Science Wants to Correct Diovan Paper, Sent Data Found During Diovan Probe to US Journal
December 27, 2013
- Chuikyo Reps Slam Inter-Ministerial Deal to Scrap Insurance Coverage for Gargles
December 27, 2013
- Chuikyo Approves 60% Upper Limit for Evaluating Generic Drug Use at DPC Hospitals
December 27, 2013
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
- MHLW Pitches Dispensing Fee Cuts for Hospitals, Pharmacies with Low Price Settlement Rates
December 26, 2013
- Active Recommendation for HPV Vaccines Remains Suspended
December 26, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…